Canada markets open in 2 hours 33 minutes

Mesoblast Limited (MEOBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.48000.0000 (0.00%)
At close: 11:37AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.4800
Open0.4800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4800 - 0.4800
52 Week Range0.4400 - 1.5200
Volume2,500
Avg. Volume1,358
Market Cap312.218M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-0.1420
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    The past five years for Mesoblast (ASX:MSB) investors has not been profitable

    We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...

  • GlobeNewswire

    Mesoblast Key Opinion Leader Event Series for Investors & Analysts

    Chronic Low Back Pain due to Degenerative Disc DiseaseNEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the current treatment landscape and unmet medical need for patients with chronic low back pain (CLBP) due to degenerative disc disease, a condition associated with local inflammation in the disc. The webinar will feature presentations from Key Opinion Lea

  • GlobeNewswire

    Operational Highlights and Financial Results for the Period Ended March 31, 2022

    Substantial Reduction in Operational Spend while Maintaining Focus on BLA ResubmissionNEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended March 31, 2022. Financial Highlights Net cash usage reported for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 million compared with U